Targeted Tumor Mutation Testing
The GeneStrat targeted test evaluates the presence of actionable mutations in NSCLC. The test is covered independent of stage and can be used multiple times per patient to monitor changes in mutation status.
Not restricted by stage of NSCLC or recurrence
Extracts cfDNA and cRNA to detect fusions, indels, and point mutations
Download Sample Test Report
Download sample test report. Easily identify if tumor mutations were detected in cfDNA or cRNA on the two-page report.
Broad Tumor Mutation Testing
The GeneStrat NGS test is a broad 52 gene panel, including guideline recommended mutations that help identify advanced stage patients eligible for targeted therapy or clinical trial enrollment.
Detects Single Nucleotide Variants (SNV), Insertion/deletions (Indels), Copy Number Amplifications (CNA), Fusion and Skipping Variants
Supports multi-disciplinary collaboration
Download Sample Test Report
Identify actionable findings, including guideline recommended treatment options and active clinical trials in this concise, intuitive test report.
Host Immune Profile Testing
The VeriStrat test is a novel blood-based host immune classifier (HIC) for patients with non-small cell lung cancer. Clinical studies have shown that the test is predictive and prognostic of outcomes independent of ECOG performance status, mutation status, PD-L1 expression, treatment choice, and line of therapy.
Kaplan-Meier analysis of overall survival in patients with advanced stage NSCLC receiving ICI as monotherapy or ICI in combination with chemotherapy by HIC classification in the subsets of patients with high PD-L1 expression and ECOG PS 0-1..png?width=800&height=300&name=VS%20TRR%20Graph%20Only%20(004).png)
Download Sample Test Report
Download sample test report. Quickly identify a patient's VeriStrat status in this two-page report.
